13:30am Chair Introduction

Chairperson: Tomer Bronshtein, Vice President, Business Development, Bonus Biogroup 

13:35am Presentation: Designing and Delivering Next-Generation TCR T-cell Therapies

• The development of afami-cel for synovial sarcoma and progress towards BLA 
• Improving efficacy for other solid tumours with a next-gen TCR product incorporating CD8α 

Jo Brewer, Chief Scientific Officer, Adaptimmune

13:50am Presentation: Cilta-cel: The Story of a Llama-Inspired, Autologous CAR-T Product for Multiple Myeloma

• Describe the development of Cilta-cel 
• Review of the safety and efficacy of Cilta-cel for myeloma, including early phase and randomized studies 
• Discuss the future applications of autologous CAR-T for myeloma 

Jordan Schechter, Vice President, Clinical Development, Cellular Therapy, Janssen

14:05am Presentation: Enhancing efficacy of CAR T-cells against solid tumours by optimising CAR structure. 

• Efficacy of CAR T-cells against the majority of solid tumours has been underwhelming. 
• Optimisation of CAR structure from a linear to a lateral conformation significantly enhances T-cell function. 
• T-cells expressing lateral CARs provide the perfect chassis with which to pair appropriate armouring technologies.

Marc Davies, Vice President of R&D, Leucid Bio

14:20pm Closing Panel with Q&A

With all session participants